Acute myeloid leukemia (AML) is an aggressive blood cancer arising from the uncontrolled growth of immature myeloid cells in the bone marrow. It typically affects older adults and progresses rapidly, making early diagnosis and prompt treatment critical.

Genetically, AML is highly heterogeneous. Recurrent chromosomal abnormalities and gene mutations shape disease behavior and prognosis. Commonly altered genes include FLT3, NPM1, IDH1 and IDH2, along with others affecting signaling, epigenetic regulation and transcription. Specific combinations of mutations and cytogenetic changes define risk groups that guide therapy and transplant decisions.

Standard treatment still centers on intensive induction chemotherapy to achieve complete remission, followed by consolidation with further chemotherapy or allogeneic stem cell transplantation in eligible patients. However, long term cure rates remain limited, especially in older or unfit individuals.

Recent research has transformed the therapeutic landscape. Targeted inhibitors now exist for FLT3 and IDH1 or IDH2 mutated disease, and for BCL2 dependent leukemic cells. These drugs are often combined with low intensity regimens like hypomethylating agents, improving survival and allowing treatment of frailer patients. Antibody based approaches, such as CD33 targeted conjugates, and emerging cellular immunotherapies including CAR T and NK cell strategies, aim to selectively eradicate leukemic cells.

Other advances include better measurable residual disease monitoring using molecular and flow cytometric techniques, which refines risk assessment and informs treatment adaptation. Ongoing studies focus on overcoming resistance, rational drug combinations, and exploiting leukemic stem cell vulnerabilities. Together, these developments are moving AML management from uniform chemotherapy toward precise, mutation guided and immune informed therapy.